The Study for Efficacy of Adalimumab Maintenance Therapy Initiated Following Resection of Active Lesions in Crohn's Disease Patients

Phase 2

• Conditions: Crohn' s disease Patients who has been treated with following surgical removal of active lesions(intestinal resection)

• Registration Number: JPRN-UMIN000009284
• Lead Sponsor: Sakura Medical Center,Toho university

Brief Summary

clinical remission rate at 12months was 70.0% endoscopic remission rate at 12months was 62.5%

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-11-20
• Study Completion: 2014-11-19
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1the patient of contraindication for adalimumab 2pregnancy 3the patient who is short bowel syndrome 4the patient who is not able to calculate CDAI 5the patient with stoma 6the case which is hard to get the patient's consent 7the patient who was judged for insuitable by responsibility doctor

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
remission maintenance rate of adalimumab maintenance therapy ,evaluated by CDAI score 12months after intestinal resection.

Secondary Outcome Measures

Name	Time	Method
remission maintenance rate 6months and 12months after intestinal resection, evaluated by CDAI score and C-reactive protein. remission maintenae rate 6months and 12months after intestinal resection, evaluated by endoscopic score(Rutgeerts score)